The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes

Drago, Antonio; Crisafulli, Concetta; Sidoti, Antonina; Serretti, Alessandro

doi:10.1016/j.pneurobio.2011.05.009

Cited by 62 publications

(41 citation statements)

References 419 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent case-control study of 14 genetic variants within the CREB, CREB binding protein (CREBBP) and cAMP response element-modulator (CREM) found no association between these genes and diagnosis and treatment response in patients with MDD and bipolar disorder [151]. In conclusion, referring to signal transduction and transcription factors, the above genes have been only marginally investigated and a number of promising genes for their biological function have been proposed (e.g., CAMK2 subtypes, MAPK3 and 1, PRKAR subtypes), but not yet investigated [132].…”

Section: Crisafulli C Et Al: Pharmacogenetics Of Antidepressant Drugmentioning

confidence: 97%

“…In recent years, the glutamatergic theory of depression has gained growing interest, as many studies have documented the important role played by the glutamatergic system in the pathophysiology of depression and mechanism of action of ADs [131,132]. A number of pharmacogenetic studies have evaluated the effect of different glutamatergic polymorphisms on treatment outcome in MDD.…”

Section: Glutamatergic Systemmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenetics of antidepressant drugs: An update

Crisafulli¹,

Drago²,

Calabrò³

et al. 2014

Hosp Pharm Int Multi J

Self Cite

View full text Add to dashboard Cite

SUMMARYPharmacological treatment of depressive disorders is characterized by poor predictability of individual response. In recent years, the increasing evidence has demonstrated that genetic factors play a critical role in determining the differences in treatment outcome to antidepressant drugs. A number of pharmacogenetic studies on antidepressant drugs has been conducted, and genetic variations at level of drug metabolizing enzymes, drug transporters and drug targets, possibly influencing the clinical response, have been identified. Pharmacogenetics may hopefully provide the basis for individualized pharmacotherapy of depressive disorders in order to maximize the probability of a favorable response and minimize the risk of adverse drug reactions. In this article, the major findings related to the pharmacogenetics of genes involved in the pharmacokinetics and pharmacodynamics of antidepressant drugs are critically reviewed.

show abstract

Section: Crisafulli C Et Al: Pharmacogenetics Of Antidepressant Drugmentioning

confidence: 97%

Section: Glutamatergic Systemmentioning

confidence: 99%

Pharmacogenetics of antidepressant drugs: An update

Crisafulli¹,

Drago²,

Calabrò³

et al. 2014

Hosp Pharm Int Multi J

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, noradrenaline is involved in release and uptake of glutamate [114]. Glutamate is the principal excitatory, γ-aminobutyric acid (GABA) the predominant inhibitory neurotransmitter in the brain, both occupying at least 50% of the synapses.…”

Section: Neurotransmitter Hypothesesmentioning

confidence: 99%

Neurobiological Background of Affective Disorders

Falkai¹,

Malchow²,

Schmitt³

2013

Psychiatric Disorders - New Frontiers in Affective Disorders

View full text Add to dashboard Cite

“…There is a close association between MAPK1 and CREB1 as they are both involved in the regulation of neuronal plasticity and inflammatory pathways [82], which retain a fundamental role in the pathophysiology of MDD [75]. Furthermore, an association between CREB1 and response to antidepressants [83] and mood stabilizers [84] has been found.…”

Section: Introductionmentioning

confidence: 99%

Clinical and genetic factors associated with suicide in mood disorder patients

Antypa¹,

Souery²,

Tomasini³

et al. 2015

Eur Arch Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

stronger predictor of current suicide risk. No associations were found with polymorphisms within COMT and BDNF genes, whereas significant associations were found with variations in rs13515 (MAPK1) and rs6740584 (CREB1) polymorphisms. From a clinical perspective, our study proposes several clinical characteristics, such as increased depressive symptomatology, anxiety comorbidity, functional disability and family history of suicidality, as correlates associated with suicide. Genetic risk variants in MAPK1 and CREB1 genes might be involved in a dysregulation of inflammatory and neuroplasticity pathways and are worthy of future investigation.

show abstract

The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes

Cited by 62 publications

References 419 publications

Pharmacogenetics of antidepressant drugs: An update

Pharmacogenetics of antidepressant drugs: An update

Neurobiological Background of Affective Disorders

Clinical and genetic factors associated with suicide in mood disorder patients

Contact Info

Product

Resources

About